Prepared by R.R. Donnelley Financial -- EX-10.17(b)




 Exhibit 10.17(b) 

 

CONFIDENTIAL 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 

 AMENDMENT #1 TO TASK ORDER #20

 COHERUS Project Number: CHS-0214-04 

MEDPACE Project Number: ETA304 

This Amendment #1 (“Amendment #1”) to Task Order #20 effective as of November 8, 2013 (“Task Order”), is by and
between Coherus Biosciences, Inc., a Delaware corporation with its principal place of business at 201 Redwood Shores Parkway, Suite 200, Redwood City, CA 94065 (“Sponsor”), and Medpace, Inc., with its principal place of
business at 5375 Medpace Way, Cincinnati, Ohio 45227 (“Medpace”). This Amendment #1 shall be effective April 23, 2014. 

WITNESSETH: 

WHEREAS, the Parties have entered into Task Order pursuant and subject to the terms of the Master Service Agreement dated
January 23, 2012, (the “Agreement”); and 
 WHEREAS, the Parties desire to amend Task Order in connection with A Phase
3, Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel® in Subjects With Chronic Plaque Psoriasis (PsO) to add Medpace
Reference Laboratories (“MRL”) Services and Fees, which includes [***] vendor services. 
 NOW, THEREFORE, in consideration
of the mutual covenants contained herein, the Parties hereby agree as follows to the revised Scope of Work. 
  

	 	1.	Appendix A: Scope of Work, attached to Task Order #20 is hereby amended to include MRL and [***] start-up services included in Appendix F attached to this Amendment #1. 


 

	 	2.	Appendix C: Budget, attached to Task Order #20 is hereby amended to include MRL and [***] fees included in Appendix F attached to this Amendment #1. 


 

	 	3.	As a result of the increase in the Budget, Appendix D: Payment Schedule, attached to Task Order #20 is hereby amended to increase the [***] upfront payment of Pass-through Costs by [***], which increase is due upon
execution of this Amendment #1. 


  

			
	



	  	 Medpace Amendment #1 to Task Order #20

Coherus Biosciences, Inc.
 CHS-0214-04 /
ETA 304
  Page
 1












 The total amount payable by Sponsor to Medpace under this Amendment #1 for Medpace Direct Fees, Pass-through
Expenses, and Pre-funded Expenses shall not exceed the amount of [***] without prior written consent of both parties. The total value of Task Order and all subsequent amendments is now [***]. 

 

																	
	 	  	Direct Fees	 	 	Pass Through Costs	 	 	Pre-funded Expenses	 	 	TOTAL	 
					
	 Task Order #20
	  	 	[	***] 	 	 	[	***] 	 	 	[	***] 	 	 	[	***] 
					
	 Amendment #1
	  	 	[	***] 	 	 	[	***] 	 	 	[	***] 	 	 	[	***] 
					
	 TOTAL
	  	 	[	***] 	 	 	[	***] 	 	 	[	***] 	 	 	[	***] 

 All other provisions of the Agreement and Task Order shall remain unchanged and in effect. 

IN WITNESS WHEREOF, the Parties have hereunto signed this Amendment #1 to Task Order in their official capacities which shall be effective on the day
and year listed above. 
  

			
	MEDPACE, INC.
		
	Signature:	 	/s/ John Wynne


			
		
	By:	 	John Wynne
		 	(Print Name)


			
		
	Title:	 	Vice President Commercial Operations

  

			
	COHERUS BIOSCIENCES, INC.
		
	Signature:	 	/s/ Dennis M. Lanfear


			
		
	By:	 	Dennis M. Lanfear
		 	(Print Name)


			
		
	Title:	 	Chief Executive Officer


  
 [***] Certain
information in this document has been omitted and filed separately with the Securities and 
 Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 
  



			
	



	  	 Medpace Amendment #1 to Task Order #20

Coherus Biosciences, Inc.
 CHS-0214-04 /
ETA 304
  Page
 2












 APPENDIX F: MRL AND [***] Services and Budget 

 

					
	Sponsor:	    	Coherus Biosciences	  	23-Apr-14
	Protocol:	    	CHS-0214-04 Start-up	  	

  
  

							
	 [***]
	  		  	 	[	***] 
		  	[***]	  	 	[	***] 
		  	[***]	  	 	[	***] 
	 Total Medpace Reference Laboratories Fees
	  		  	 	[	***] 

  

											
	Medpace Reference Laboratories Fee Estimate
	 Sponsor: Coherus Biosciences

Protocol: CHS-0214-04 Start-up
	  	

[***]
			
	 	  	 	  	Number of Analyses Per Visit
						
	 	  	Unit Cost	  	Screening
W-4	  	Total
Number
of Units	  	Cost	  	Subtotal
	Laboratory Tests	  	 	  	 	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
						
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
						
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
	Laboratory/Support
Services	  	 	  	 	  	[***]
	[***]	  	 	  	 	  	 	  	 
	[***]	  	[***]	  		  	[***]	  	[***]	  	
	[***]	  	[***]	  		  		  		  	
	[***]	  	[***]	  		  		  		  	
	[***]	  	[***]	  		  	[***]	  	[***]	  	
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
	[***]	  	[***]	  		  		  		  	
	[***]	  	[***]	  		  	[***]	  	[***]	  	
	[***]	  	[***]	  		  	[***]	  	[***]	  	
	[***]	  	 	  	 	  	 	  	 
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
	[***]	  	[***]	  		  	[***]	  	[***]	  	
	[***]	  	[***]	  		  	[***]	  	[***]	  	
	[***]	  	[***]	  		  	[***]	  	[***]	  	
	[***]	  	[***]	  		  	[***]	  	[***]	  	
	Total Medpace Reference Laboratory Fees	  	 	  	 	  	[***]


  
 [***] Certain
information in this document has been omitted and filed separately with the Securities and 
 Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 
  



			
	



	  	 Medpace Amendment #1 to Task Order #20

Coherus Biosciences, Inc.
 CHS-0214-04 /
ETA 304
  Page
 3













					
	Medpace Reference Laboratories Pass Through Estimate
	 Sponsor: Coherus Biosciences

Protocol: CHS-0214-04 Start-up
	  		  	
	 	  	Total Cost	  	Subtotal
	Pass Through Estimates	  	 	  	[***]
	 [***]
	  	 	  	 
	[***]	  	[***]	  	
	[***]	  	[***]	  	
	Total Estimated Medpace Reference Laboratory Pass-Through Fees	  		  	[***]

 Transportation Costs 
  

																									
	Country	  	Sites	  	Number
Screened	  	Number
Ambient /
Refrigerate
shipments	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	 
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
	Total	  	[***]	  	[***]	  	[***]	  		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]	  	
		  		  		  		  		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]	  	[***]


  
 [***] Certain
information in this document has been omitted and filed separately with the Securities and 
 Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 
  



			
	



	  	 Medpace Amendment #1 to Task Order #20

Coherus Biosciences, Inc.
 CHS-0214-04 /
ETA 304
  Page
 4












 [***] 

[***] 
 CONFIDENTIAL 

 

					
	 [***]
	  	 	[	***] 
	 [***]
	  	 	[	***] 

  

																									
	 Date, Version: [***]

Prepared by [***]: [***]

Prepared for [***]: [***]

Client & Protocol: Medpace – CHS-0214-04

Phase: III

[***]: [***]

[***]: [***]

[***]: [***]

[***]: [***]

[***]: [***]
	  	 
 	Unit 
Price [***]	 
  	 	 	[***]	  	 	 	[***]	  	 	 	[***]	  	 	 	[***]	  	 	 	Total [***]	  
	 [***]: [***]
	  				 				 	 	[	***] 	 	 	[	***] 	 	 	[	***] 	 			
	 [***]: [***]
	  				 				 	 	[	***] 	 	 	[	***] 	 	 	[	***] 	 			
	 [***]: [***]
	  				 				 	 	[	***] 	 	 	[	***] 	 	 	[	***] 	 			
	 [***]: [***]
	  				 				 	 	[	***] 	 	 	[	***] 	 	 	[	***] 	 			
	 [***]
	  				 				 	 	[	***] 	 	 	[	***] 	 	 	[	***] 	 	 	[	***] 
	 [***]
	  				 				 	 	[	***] 	 	 	[	***] 	 	 	[	***] 	 	 	[	***] 
	 [***]
	  				 				 	 	[	***] 	 	 	[	***] 	 	 	[	***] 	 	 	[	***] 
	 [***]
	  				 				 				 				 				 	 	[	***] 
	 [***]
	  				 				 				 				 				 			
	 [***]
	  	 	[	***] 	 	 	[	***] 	 				 				 				 	 	[	***] 
	 [***]
	  	 	[	***] 	 	 	[	***] 	 				 				 				 	 	[	***] 
	 [***]
	  	 	[	***] 	 	 	[	***] 	 				 				 				 	 	[	***] 
	 [***]
	  	 	[	***] 	 	 	[	***] 	 				 				 				 	 	[	***] 
	 [***]
	  	 	[	***] 	 	 	[	***] 	 				 				 				 	 	[	***] 
	 [***]
	  	 	[	***] 	 	 	[	***] 	 				 				 				 	 	[	***] 
	 [***]
	  	 	[	***] 	 	 	[	***] 	 				 				 				 	 	[	***] 
	 [***]
	  				 				 				 				 				 	 	[	***] 
	 [***]
	  				 				 				 				 				 	 	[	***] 
	 [***]
	  				 				 	 	[	***] 	 	 	[	***] 	 	 	[	***] 	 	 	[	***] 
	 Total [***]
	  				 				 				 				 				 	 	[	***] 

 “[***]. 
 Notes: 

	1.	[***] 


	2.	[***] 


	3.	[***] 


	4.	[***] 


	5.	[***] 


	6.	[***] 


	7.	[***] 


	8.	[***] 


	9.	[***] 


	10.	[***] 


	11.	[***] 

 ASSUMPTIONS: 

	1.	[***] 


	2.	[***] 


  
 [***] Certain
information in this document has been omitted and filed separately with the Securities and 
 Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 









 [***] Estimated Budget 

CONFIDENTIAL 
 [***]: [***]

  

																									
	 [***]
	  	 	[	***] 	 				 				 				 				 			
	 [***]
	  	 	[	***] 	 				 				 				 				 			
	 [***]

Date, Version: [***]

Client Protocol: Medpace – CHS-0214-04

[***]: [***]

[***]: [***]

[***]: [***]

[***]: [***]
	  	 
 	Unit Price
[***]	  
  	 	 	[***]	  	 	 	[***]	  	 	 	[***]	  	 	 	[***]	  	 	 	Total [***]	  
	 [***]
	  				 				 				 				 				 			
	 [***]
	  	 	[	***] 	 	 	[	***] 	 	 	[	***] 	 	 	[	***] 	 	 	[	***] 	 	 	[	***] 
	 [***]
	  				 				 				 				 				 	 	[	***] 
	 [***]
	  				 				 				 				 				 			
	 [***]
	  	 	[	***] 	 				 				 				 				 	 	[	***] 
	 [***]
	  	 	[	***] 	 				 				 				 				 	 	[	***] 
	 [***]
	  				 				 				 				 				 	 	[	***] 
	 [***]
	  				 				 				 				 				 			
	 [***]
	  	 	[	***] 	 	 	[	***] 	 	 	[	***] 	 	 	[	***] 	 	 	[	***] 	 	 	[	***] 
	 [***]
	  	 	[	***] 	 				 				 				 	 	[	***] 	 	 	[	***] 
	 [***]
	  				 				 				 				 				 	 	[	***] 
	 Total [***]
	  				 				 				 				 				 	 	[	***] 

 [***] Notes: 

	1.	[***] 

 Additional [***] Clinical Trials Services 

 

					
	 [***]
	  		  	[***]
	 [***]
	  	[***]	  	
	 [***]
	  	[***]	  	
	 [***]
	  	[***]	  	

  

													
	 [***]
	  	Unit Price
 [***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	Total [***]
	 [***]
	  		 		 		 		 		 	
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  		 		 		 		 		 	
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  		 		 		 		 		 	
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 Total [***]
	 		 		 	[***]

 [***] Notes: 

  
 [***] Certain
information in this document has been omitted and filed separately with the Securities and 
 Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 









 [***] Estimated Budget 

CONFIDENTIAL 
 [***]: [***]

  

															
	 [***]
	  	[***]	 		 		 		 		 		 	
	 [***]
	  	[***]	 		 		 		 		 		 	
	 [***]

Date, Version: [***]

Client Protocol: Medpace – CHS-0214-04

[***]: [***]

[***]: [***]

[***]: [***]

[***]: [***]
	  	Unit Price
[***]	 	Unit Price
[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	Total [***]
	 [***]
	  		 		 		 		 		 		 	
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  		 		 		 		 		 		 	[***]
	 [***]
	  		 		 		 		 		 		 	
	 [***]
	  		 		 		 		 		 		 	[***]
	 [***]
	  		 		 		 		 		 		 	
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  		 		 		 		 		 		 	[***]
	 Total [***]
	  		 		 		 		 		 		 	[***]

 [***] Notes: 

	1.	[***] 

 Additional [***] Clinical Trials Services 

 

					
	 [***]
	  		  	[***]
	 [***]
	  	[***]	  	
	 [***]
	  	[***]	  	
	 [***]
	  	[***]	  	

  

															
	[***]	  	Unit Price
[***]	 	Unit Price
[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	Total [***]
	 [***]
	  		 		 		 		 		 		 	
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  		 		 		 		 		 		 	
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  		 		 		 		 		 		 	
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  		 		 		 		 		 		 	
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  		 		 		 		 		 		 	
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  		 		 		 		 		 		 	
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  		 		 		 		 		 		 	
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 Total [***]
	 		 		 	[***]

 [***] Notes: 
 [***]


	1.	[***] 


  
 [***] Certain
information in this document has been omitted and filed separately with the Securities and 
 Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 









 [***] Estimated Budget 

CONFIDENTIAL 
 [***]: [***]

  

															
	 [***]
	  	[***]	  		  		  		  		  		  	
	 [***]
	  	[***]	  		  		  		  		  		  	
	 [***]
 Date, Version: [***]

Client Protocol: Medpace – CHS-0214-04

[***]: [***]

[***]: [***]

[***]: [***]

[***]: [***]
	  	Unit Price
[***]	  	Unit Price
[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	Total [***]
	 [***]
	  		  		  		  		  		  		  	
	 [***]
	  	See [***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
	[***]	  		  		  		  		  		  		  	[***]
	 [***]
	  		  		  		  		  		  		  	
	[***]	  		  		  		  		  		  		  	[***]
	 [***]
	  		  		  		  		  		  		  	
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  		  		  		  		  		  		  	[***]
	Total [***]	  		  		  		  		  		  		  	[***]

 [***] Notes: 

	1.	[***] 

 Additional [***] Clinical Trials Services 

 

					
	 [***]
	  		  	[***]
	 [***]
	  	[***]	  	
	 [***]
	  	[***]	  	
	 [***]
	  	[***]	  	
	 [***]
	  	[***]	  	
	 [***]
	  	[***]	  	

  

																	
	[***]	  	[***]	 	Unit
Price	 	Unit
Price
[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	Total [***]
	 [***]
	  		 		 		 		 		 	
	 [***]
	  	[***]	 		 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	  	[***]	 		 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]
	 [***]
	  	[***]	 		 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***][***]
	 [***]
	  		 		 		 		 		 	
	 [***]
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 Total [***]
	 	[***]

 [***] Notes: 
 [***]


  
 [***] Certain
information in this document has been omitted and filed separately with the Securities and 
 Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions. 









 CONFIDENTIAL 

[***] 
  

															
		  		  		  		  	[***]	  		  	[***]	  	
	I	  	[***]	  		  		  		  		  		  	
								
		  	[***]	  		  		  		  		  		  	
								
		  	 [***]
	  		  	[***]	  		  	[***]	  		  	[***]
								
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
								
	II	  	[***]	  		  		  		  		  		  	
								
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
								
	III.	  	[***]	  		  		  		  		  		  	
								
		  	[***]	  		  		  		  		  		  	
		  	[***]	  		  		  		  		  		  	
								
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	 [***]
	  		  		  		  		  		  	
								
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
								
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
								
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
								
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	 [***]
	  		  		  		  		  		  	
		  	 [***]
	  		  		  		  		  		  	
								
		  	[***]	  	[***]	  		  		  		  		  	
		  	 [***]
	  	[***]	  		  		  		  		  	
		  	 [***]
	  		  		  		  		  		  	
								
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  	[***]	  		  	[***]	  		  	[***]	  		  	[***]
		  		  		  		  		  		  		  	


  
 [***] Certain
information in this document has been omitted and filed separately with the Securities and 
 Exchange Commission. Confidential treatment has
been requested with respect to the omitted portions.